Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Hairy cell leukemia variant in a patient with chronic myeloid leukemia receiving nilotinib: sequential or coincidental?

Gopaluni S, Sanyal S, Bair A, Vajpayee N.

J Clin Oncol. 2012 Feb 10;30(5):e58-61. doi: 10.1200/JCO.2011.38.1392. No abstract available.

PMID:
22184394
2.

Megakaryocyte features and bcr/abl translocation in chronic myeloid leukemia following imatinib mesylate (STI571) therapy--a fluorescence in-situ hybridization study.

Thiele J, Kvasnicka HM, Varus E, Ollig E, Schmitt-Graeff A, Staib P, Griesshammer M.

Leuk Lymphoma. 2004 Aug;45(8):1627-31.

PMID:
15370216
3.

Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR-ABL kinase domain.

Stagno F, Vigneri P, Del Fabro V, Stella S, Massimino M, Berretta S, Cupri A, Consoli C, Messina L, Tirrò E, Messina A, Di Raimondo F.

Leuk Res. 2009 Sep;33(9):e157-8. doi: 10.1016/j.leukres.2009.03.040. No abstract available.

PMID:
19406471
4.

Case report and literature review: a rare patient with chronic myeloid leukemia and chronic lymphocytic leukemia.

Bhagavathi S, Borromeo V, Desai H, Crisan D.

Ann Clin Lab Sci. 2008 Autumn;38(4):405-9.

PMID:
18988937
5.

Chronic phase of ETV6-ABL1 positive CML responds to imatinib.

Kawamata N, Dashti A, Lu D, Miller B, Koeffler HP, Schreck R, Moore S, Ogawa S.

Genes Chromosomes Cancer. 2008 Oct;47(10):919-21. doi: 10.1002/gcc.20593. No abstract available.

PMID:
18615681
6.

The expanding role of nilotinib in chronic myeloid leukemia.

Kim TD, le Coutre P.

Expert Opin Drug Saf. 2011 Jan;10(1):97-107. doi: 10.1517/14740338.2011.532486. Review.

PMID:
21121868
7.

Bullous sweet syndrome in a patient with t(9;22)(q34;q11)-positive chronic myeloid leukemia treated with the tyrosine kinase inhibitor nilotinib: interphase cytogenetic detection of BCR-ABL- positive lesional cells.

Kaune KM, Baumgart M, Gesk S, Mitteldorf C, Baesecke J, Glass B, Haase D, Siebert R, Ghadimi BM, Neumann C, Emmert S.

Arch Dermatol. 2008 Mar;144(3):361-4. doi: 10.1001/archderm.144.3.361.

PMID:
18347292
8.

Nilotinib (Tasigna) for CML.

[No authors listed]

Med Lett Drugs Ther. 2008 Apr 7;50(1283):26-7. No abstract available.

PMID:
18391899
9.

Very late relapse in a patient with chronic myeloid leukemia in sustained complete cytogenetic response under imatinib.

Defina M, Gozzetti A, Rondoni M, Aprile L, Ippoliti M, Chitarrelli I, Lauria F, Bocchia M.

Leuk Res. 2010 Aug;34(8):e215-6. doi: 10.1016/j.leukres.2010.02.037. No abstract available.

PMID:
20334915
10.

Complete cytogenetic and molecular response to treatment with imatinib mesylate for philadelphia chromosome positive acute myeloid leukemia with multilineage dysplasia.

Ueda K, Horiike S, Zen K, Misawa S, Taniwaki M.

Leuk Lymphoma. 2006 Sep;47(9):1967-9. No abstract available.

PMID:
17065015
11.

The simultaneous occurrence of variant hairy cell leukemia and chronic-phase chronic myelogenous leukemia. A case report.

Reeves JE, Robbins BA, Pankey LR, Elias AL, Anderson WF.

Cancer. 1995 Apr 15;75(8):2089-92.

PMID:
7697598
12.

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.

Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL, Arber DA, Slovak ML, Forman SJ.

Blood. 2003 Jun 15;101(12):4701-7.

PMID:
12576334
13.

Concomitant use of imatinib and warfarin in chronic phase chronic myeloid leukemia patients does not interfere with drug efficacy.

Breccia M, Santopietro M, Loglisci G, Stagno F, Cannella L, Carmosino I, Alimena G.

Leuk Res. 2010 Aug;34(8):e224-5. doi: 10.1016/j.leukres.2010.03.015. No abstract available.

PMID:
20356624
14.

Roth spots in chronic myelogenous leukemia.

Kapadia RK, Steeves JH.

CMAJ. 2011 Dec 13;183(18):E1352. doi: 10.1503/cmaj.100561. No abstract available.

PMID:
21930739
15.

[Chronic myeloid leukemia and imatinib mesylate therapy].

Chrobák L.

Vnitr Lek. 2004 Jan;50(1):10-2. Czech. No abstract available.

PMID:
15015223
16.

Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

Goldman JM, Melo JV.

N Engl J Med. 2001 Apr 5;344(14):1084-6. No abstract available.

PMID:
11287980
17.

Is telomerase a player in chronic phase chronic myeloid leukemia, disease progression and imatinib resistance?

White DL.

Leuk Lymphoma. 2008 Jun;49(6):1022-3. doi: 10.1080/10428190802074635. No abstract available.

PMID:
18452091
18.

Does early imatinib-induced myelosuppression predict hematologic responses in patients with advanced-phase chronic myeloid leukemia?

Cashen A, DiPersio JF, Khoury H.

J Clin Oncol. 2003 Nov 15;21(22):4255-6. No abstract available.

PMID:
14615462
19.

Absence of histological myopathy in chronic myeloid leukemia patients complaining of muscle spasms and myalgia during treatment with nilotinib.

Caocci G, Maioli MA, Atzeni S, Piras R, Carboni N, La Nasa G.

Leuk Res. 2012 Sep;36(9):e206-8. doi: 10.1016/j.leukres.2012.06.006. No abstract available.

PMID:
22742815
20.

[The 2nd generation of TKIs for chronic myeloid leukemia].

Matsumura I.

Rinsho Ketsueki. 2010 Oct;51(10):1386-94. Japanese. No abstract available.

PMID:
20962471
Items per page

Supplemental Content

Support Center